Back to search results

Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type

Abroad (travel likely)RecruitingPHASE2

Conditions

Agitation

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Arrow Clinical Trials, Daytona Beach, Florida, United States

    Contact: Study coordinator (Andrew White) · awhite@arrowtrials.com · 386-278-8000
    Contact: Principal Investigator (David Billmeier, MD)

  • Global Medical Institutes Florida LLC, Miami, Florida, United States

    Contact: Study coordinator (Melissa Matienzo) · mmatienzo@gminstitutes.com · 305-547-2011
    Contact: Principal Investigator (Leonardo Alonso, MD)
    Magaly Alonso, MD (Sub-investigator)

  • Professional Health Care of Pinellas, LLC, St. Petersburg, Florida, United States

    Contact: Study coordinator (Melissa Suarez) · msuarez@phcpinellas.com · 727-820-1033
    Contact: Principal Investigator (Fadi Saba, MD)

  • Elixia MA, LLC, Springfield, Massachusetts, United States

  • Vitalix, Worcester, Massachusetts, United States

    Contact: Study coordinator (Matthew Collins) · mcollins@vitalixclinical.com · 413-363-5206
    Contact: Principal Investigator (James Carroll, MD)

  • BioBehavioral Health, Toms River, New Jersey, United States

    Contact: Study coordinator (Madison Filtcraft) · labtech@bbhnj.com · 732-244-2299
    Contact: Principal Investigator (Ashok Patel, MD)
Study leads

  • Tami Ujiie

    Study Director

    Teikoku Pharma USA, Inc.

View source on ClinicalTrials.gov(opens in a new tab)